

Attorney Docket No.: KUZ0028US.NP
Inventors: Tateishi et al.
Serial No.: 10/566,350
Filing Date: January 27, 2006
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): An adhesive patch ~~having~~ consisting essentially of a release liner, a drug-containing pressure-sensitive adhesive layer comprising bisoprolol or a pharmaceutically acceptable salt of bisoprolol, wherein said adhesive layer is a matrix type, and the composition thereof contains thereof, styrene-isoprene-styrene block copolymer and/or polyisobutylene, 2-ethylhexyl acrylate·vinyl acetate·acrylic acid copolymer, isopropyl myristate, sodium acetate, and the penetration rate of bisoprolol through skin is 4-300 $\mu\text{g}/\text{h}\cdot\text{cm}^2$ a plasticizer and a tackifying resin, and a backing layer contacting the drug-containing pressure-sensitive adhesive layer on a side opposite to the release liner.

Claims 2-10 (canceled)

Claim 11 (previously presented): The adhesive patch according to claim 1, wherein the pharmaceutically acceptable salt of bisoprolol is bisoprolol hemifumarate.

Claims 12-21 (canceled)

Claim 22 (previously presented): The adhesive patch according to claim 1, wherein the penetration rate of bisoprolol through the skin is between 4 and 54.3 $\mu\text{g}/\text{h}\cdot\text{cm}^2$.

Attorney Docket No.: KUZ0028US.NP
Inventors: Tateishi et al.
Serial No.: 10/566,350
Filing Date: January 27, 2006
Page 4

Claim 23 (currently amended): The adhesive patch according to claim 1, wherein the drug-containing pressure-sensitive adhesive layer contains 0.1 to 10 wt % of sodium acetate based on the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claim 24 (currently amended): The adhesive patch according to claim 23, wherein the drug-containing pressure-sensitive adhesive layer contains 4.5 to 8.5 wt % of sodium acetate based on the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claim 25 (currently amended): The adhesive patch according to claim 1, wherein the drug-containing pressure-sensitive adhesive layer contains 0.1 to 20 wt % of isopropyl myristate based on the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claim 26 (currently amended): The adhesive patch according to claim 25, wherein the drug-containing pressure-sensitive adhesive layer contains 10 to 15 wt % of isopropyl myristate based on the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claim 27 (canceled)

Claim 28 (currently amended): The adhesive patch according to claim 22, wherein the drug-containing pressure-sensitive adhesive layer contains 0.1 to 10 wt % of sodium acetate and 0.1 to 20 wt % of isopropyl myristate based on

Attorney Docket No.: KUZ0028US.NP
Inventors: Tateishi et al.
Serial No.: 10/566,350
Filing Date: January 27, 2006
Page 5

the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claim 29 (currently amended): The adhesive patch according to claim 28, wherein the drug-containing pressure-sensitive adhesive layer contains 4.5 to 8.5 wt % of sodium acetate and 10 to 15 wt% of isopropyl myristate based on the weight of the total composition of the drug-containing pressure-sensitive adhesive layer.

Claims 30-31 (canceled)

Claim 32 (new): The adhesive patch according to claim 1, wherein the penetration rate of bisoprolol through the skin is between 4 and 300 $\mu\text{g}/\text{h}\cdot\text{cm}^2$.